CRISPR gene editing has moved from laboratory curiosity to clinical treatment faster than anyone predicted. With FDA-approved therapies for sickle cell disease and beta-thalassemia already in use, 2026 marks the beginning of a new era in medicine.
Current Approved Therapies
Casgevy (exagamglogene autotemcel) became the first CRISPR-based therapy to receive FDA approval. It works by editing patients' stem cells to produce fetal hemoglobin, effectively curing sickle cell disease.
Pipeline Therapies
- In vivo CRISPR editing for hereditary angioedema (Phase III)
- CAR-T cell therapies using CRISPR-edited immune cells (multiple cancers)
- CRISPR-based diagnostics for rapid pathogen detection
- Gene editing for hereditary blindness (Phase II)